Thomas Oxley (neurologist)

Just two years later, Oxley and Synchron published a first-in-human study on the device in the Journal of NeuroInterventional Surgery. The study showed the ability of two Australians with ALS to email, text, shop, and bank online using the Stentrode Device, and was conducted at Royal Melbourne Hospital. Earlier in 2020, the company had announced that it received Breakthrough Device status from the US Food and Drug Administration (FDA) for the Stentrode.

Oxley and his colleagues at Mt. Sinai reported an increased incidence of stroke identified in patients under 50 years of age with COVID-19, which was published in New England Journal of Medicine in April 2020.

Dr. Oxley announced in a 2018 TEDxSydney Talk that the company, Synchron, would initiate clinical trials of the Stentrode device with the goal of assisting paralyzed patients to regain independence.

In 2018, Oxley won the 2018 Global Australian Advance Award Winner, an award given to celebrate international Australians who exhibit remarkable talent, exceptional vision and ambition, the UNESCO Netexplo award for Innovation, and was a finalist for the Congress of Neurological Surgeons Innovator of the Year Award.

After earning bachelor's degrees in medical science, medicine and surgery from the University of Monash in Melbourne Australia, Oxley earned doctorate degrees in philosophy and neuroscience from the University of Melbourne. His training included advanced MRI imaging analysis, hardware device (stent) development, and electrophysiological signal processing. Oxley completed residencies in both internal medicine and neurology, as well as a stroke fellowship. From 2015 – 2017, Oxley completed an endovascular neurosurgery fellowship at Mount Sinai Hospital in New York under Professor J. Mocco and Professor Alejandro Berenstein.

While Oxley has been conducting research in motor systems since 2003, he is said to have conceived the idea for the Stentrode™ in 2007 and he led the original team at the University of Melbourne that created the technology. Stentrode is the first motor neuroprosthesis, a form of brain-computer interface implanted via the patient's blood vessels. Oxley's team in Australia was the only non-US-based group funded by DARPA as part of the Reliable Neural-Interface Technology (RE-NET) program and led by Professor Jack Judy.